Here's a long-awaited new FDA-Approved treatment for Alzheimer's - Read more

economictimes.indiatimes.com:

Alzheimer's disease. Aducanemab (brand name Aduhelm), once hoped to be a breakthrough, received 'accelerated approval' from the FDA but reported disappointing clinical trial results. However, there is new hope for Alzheimer's treatment as the FDA grants full approval to a promising new drug named 'Lecanemab.' This drug is being sold by Eisai under the brand name 'Leqembi.' New clinical trial results for another Alzheimer's drug called 'donanemab' are also expected in the next few weeks. This drug has shown impressive preliminary results. Lecanemab could offer a fresh start in the treatment of Alzheimer's patients. The clinical data for Lecanemab shows very promising results, which the FDA approved just last month. The preliminary results from donanemab seem more impressive, but they need to be confirmed in the reports expected to be received soon. Lecanemab cannot cure Alzheimer's disease, but it has reportedly proven to slow down the loss of cognitive function. However, the long-term effects of the drug remain unknown. In a clinical trial involving 1,800 patients, Lecanemab was found to slow cognitive decline by an average of 27% over 18 months. Sanjeev Vaishnavi, a clinical neurologist at the Penn Memory Center, suggests that the logistical challenges for the drug could be daunting.

Q1:What is Alzheimer's disease? Alzheimer's disease is type of a disorder in brain that destroys memory slowly. It further leads to the inability to carry out the simplest tasks of daily routine.Q2:What causes Alzheimer's disease? Alzheimer's disease is said to be caused by the abnormal build-up of proteins around brain cells. Amyloid, is a type of protein that deposits and forms plaques around brain cells.